Overview

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma

Status:
Completed
Trial end date:
2016-08-18
Target enrollment:
Participant gender:
Summary
This study is an open label phase I/II trial to investigate the safety and efficacy of Cabozantinib for patients with relapsed or refractory myeloma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
Exelixis